Oppenheimer Assigned a Buy Rating to Healthways

By Carrie Williams

In a report released yesterday, Mohan Naidu from Oppenheimer assigned a Buy rating to Healthways (NASDAQ: HWAY), with a price target of $27. The company’s shares closed yesterday at $23.80.

According to TipRanks.com, Naidu is a 2-star analyst with an average return of 0.1% and a 47.9% success rate. Naidu covers the Technology sector, focusing on stocks such as Quality Systems, Athenahealth, and Cerner Corp.

Healthways has an analyst consensus of Moderate Buy, with a price target consensus of $27.63.

The company has a one year high of $27.30 and a one year low of $9.18. Currently, Healthways has an average volume of 790.5K.

Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HWAY in relation to earlier this year. Earlier this month, Conan Laughlin, a Director at HWAY bought 47,600 shares for a total of $602,140.

Healthways, Inc. engages in the provision of network delivered solutions and populations health management services. It is focused in the Well-Being Improvement Services segment which provides specific and personalized interventions for each individual in a population, irrespective of health status, age or payor. Its solutions involves applications for employers, health systems, health plans, and for international use. The company was founded by Stone E. Robert and Thomas G. Cigarran in 1981 and is headquartered in Franklin, TN.